Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2020 07:30 ET | Source: Immunovant

Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease

Company to Host Conference Call on March 30, 2020 at 8:30am EDT 65% mean reduction in total IgG was observed from baseline to end of treatment, with a pharmacodynamic (PD) response nearly identical...
February 14, 2020 07:00 ET | Source: Immunovant

Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019

Ended quarter with $123.5 million in cashReceived IND clearance to initiate Phase 2a trial in warm autoimmune hemolytic anemia (WAIHA) NEW YORK, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc....
February 10, 2020 07:00 ET | Source: Immunovant

Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases,...
December 19, 2019 08:00 ET | Source: Immunovant

Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation

NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Immunovant, Inc., (Nasdaq: IMVT) formerly known as Health Sciences Acquisitions Corporation (Nasdaq: HSAC) (“HSAC”), a special purpose acquisition company...
December 02, 2019 08:00 ET | Source: Immunovant

Health Sciences Acquisitions Corporation Sets Date for Special Meeting of Stockholders to Vote on Transaction with Immunovant Sciences Ltd.

NEW YORK, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Health Sciences Acquisitions Corporation ("HSAC," NASDAQ: HSAC), a special purpose acquisition company sponsored by RTW Investments, LP, announced today...
November 25, 2019 08:00 ET | Source: Immunovant

Immunovant Initiates Dosing in ASCEND-GO 2, a Phase 2b Trial of IMVT-1401 in Patients with Graves’ Ophthalmopathy (GO)

IMVT-1401, a fully human anti-FcRn antibody designed to be administered via subcutaneous injection, is the only anti-FcRn antibody known to be in clinical development for the treatment of GOTopline...